Cancer therapy using oligonucleotide-based STAT3 inhibitors: will they deliver?
about
Targeted inhibition of STATs and IRFs as a potential treatment strategy in cardiovascular diseaseCADM1 inhibits squamous cell carcinoma progression by reducing STAT3 activity.Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia.Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities.B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors.STAT3 Gene Silencing by Aptamer-siRNA Chimera as Selective Therapeutic for Glioblastoma.
P2860
Cancer therapy using oligonucleotide-based STAT3 inhibitors: will they deliver?
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Cancer therapy using oligonucleotide-based STAT3 inhibitors: will they deliver?
@en
Cancer therapy using oligonucleotide-based STAT3 inhibitors: will they deliver?
@nl
type
label
Cancer therapy using oligonucleotide-based STAT3 inhibitors: will they deliver?
@en
Cancer therapy using oligonucleotide-based STAT3 inhibitors: will they deliver?
@nl
prefLabel
Cancer therapy using oligonucleotide-based STAT3 inhibitors: will they deliver?
@en
Cancer therapy using oligonucleotide-based STAT3 inhibitors: will they deliver?
@nl
P2860
P356
P1433
P1476
Cancer therapy using oligonucleotide-based STAT3 inhibitors: will they deliver?
@en
P2093
Marcin Kortylewski
Sergey Nechaev
P2860
P304
P356
10.4155/TDE.13.152
P577
2014-03-01T00:00:00Z